Lite Strategy, Inc. (LON:0JW9)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 28.84M +87.5% |
| Revenue (ttm) | n/a |
| Net Income | -8.61M |
| EPS | -0.70 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11 |
| Average Volume | 40,180 |
| Open | 1.150 |
| Previous Close | 1.102 |
| Day's Range | 1.150 - 1.150 |
| 52-Week Range | 0.968 - 11.260 |
| Beta | 0.12 |
| RSI | 36.23 |
| Earnings Date | Feb 10, 2026 |
About Lite Strategy
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California. [Read more]
News
MEI Pharma GAAP EPS of -$0.12
MEIP Options Delisting Effective September 11th
MEIP Options Delisting Effective September 11th
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion i...
Crypto hoarding brings a stock pop for small firms—and in some cases shows patterns of possible insider trading
Cancer drug developer MEI Pharma saw its stock almost double in the days before it committed to a crypto treasury strategy.
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launc...
BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. Ac...
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.
US Stocks Likely To Open Higher Despite Trump Administration's 'Hard Deadline' Warning For Tariffs — Verizon, Domino's Pizza Earnings In Focus
U.S. stock futures were positive on Monday after ending mostly lower on Friday. Futures of major benchmark indices were higher. Commerce Secretary Howard Lutnick reiterated Aug. 1 as the “ hard deadli...
Why Is MEI Pharma Stock Soaring On Friday?
MEI Pharma, Inc. (NASDAQ: MEIP) stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro . The company on Frida...
Why Is MEI Pharma Stock Soaring On Friday?
MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
MEI Pharma soars after $100M litecoin treasury move, first public LTC holder on U.S. exchange
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (...
MEI Pharma GAAP EPS of -$0.39
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is cont...
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continu...
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is contin...
MEI Pharma Reports Fiscal Year End 2024 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the comme...
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist i...
MEI Pharma to Consider Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic altern...
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible violation...
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...